Back to top
more

Privia Health Group (PRVA)

(Delayed Data from NSDQ)

$20.58 USD

20.58
1,789,762

+1.07 (5.48%)

Updated Aug 8, 2025 03:59 PM ET

After-Market: $20.58 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 244)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Privia Health (PRVA) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Privia Health (PRVA) Misses Q2 Earnings Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -60.00% and +11.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Privia Health (PRVA) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Privia Health (PRVA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Privia Health (PRVA) Misses Q1 Earnings Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -50% and 5.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to Privia Health (PRVA) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Get a deeper insight into the potential performance of Privia Health (PRVA) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Here's What Key Metrics Tell Us About Privia Health (PRVA) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Privia Health (PRVA) Lags Q4 Earnings Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -50% and 10.37%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seeking Clues to Privia Health (PRVA) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Privia Health (PRVA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Zacks Equity Research

IRhythm Technologies (IRTC) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 103.33% and 4.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DH or PRVA: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DH vs. PRVA: Which Stock Is the Better Value Option?

Zacks Equity Research

DH vs. PRVA: Which Stock Is the Better Value Option?

by Zacks Equity Research

DH vs. PRVA: Which Stock Is the Better Value Option?

Zacks Equity Research

DH vs. PRVA: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DH vs. PRVA: Which Stock Is the Better Value Option?

Zacks Equity Research

DH or PRVA: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DH vs. PRVA: Which Stock Is the Better Value Option?

Zacks Equity Research

Compared to Estimates, Privia Health (PRVA) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Privia Health (PRVA) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Privia Health (PRVA) Misses Q3 Earnings Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -50% and 5.67%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 33.33% and 4.78%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sonendo, Inc. (SONX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Sonendo (SONX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cencora to Report Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Zacks Equity Research

Revvity to Report Q3 Earnings: What's in Store for the Stock?

by Zacks Equity Research

RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.

Zacks Equity Research

Privia Health (PRVA) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Privia Health (PRVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down

by Zacks Equity Research

Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.

Zacks Equity Research

Here's What Key Metrics Tell Us About Privia Health (PRVA) Q2 Earnings

by Zacks Equity Research

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Privia Health (PRVA) Lags Q2 Earnings Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -40% and 2.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 33.33% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Axonics (AXNX) delivered earnings and revenue surprises of 62.50% and 1.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?